Order Article Reprints

Dai WF, Arciero V, Craig E, Fraser B, Arias J, Boehm D, Bosnic N, Caetano P, Chambers C, Jones B, et al. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Current Oncology. 2021; 28(5):4174-4183. https://doi.org/10.3390/curroncol28050354

Dai, Wei Fang, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm, Nevzeta Bosnic, Patricia Caetano, Carole Chambers, Barry Jones, and et al. 2021. "Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group" Current Oncology 28, no. 5: 4174-4183. https://doi.org/10.3390/curroncol28050354

Dai, W. F., Arciero, V., Craig, E., Fraser, B., Arias, J., Boehm, D., Bosnic, N., Caetano, P., Chambers, C., Jones, B., Lungu, E., Mitera, G., Potashnik, T., Reiman, A., Ritcher, T., Beca, J. M., Denburg, A., Mercer, R. E., Parmar, A., ... on behalf of the CanREValue Collaboration Reassessment and Uptake Working Group. (2021). Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Current Oncology, 28(5), 4174-4183. https://doi.org/10.3390/curroncol28050354